We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $26.2 · 5 analysts
Stored first · Google News · Yahoo Finance (English)
Why is Azenta (AZTA) Trading So Low Despite Strong Balance Sheet - Kavout | AI
Why is Azenta (AZTA) Trading So Low Despite Strong Balance Sheet Kavout | AI
Azenta Holds Near Support as Sluggish Trading Persists - Island Reversal - dars.gov.et
Azenta Holds Near Support as Sluggish Trading Persists - Island Reversal dars.gov.et
Azenta Holds Near Support as Sluggish Trading Persists - Dynamic Hedging - DonanımHaber
Azenta Holds Near Support as Sluggish Trading Persists - Dynamic Hedging DonanımHaber
Azenta announces completion of B Medical Systems sale to Thelema S.a r.l; Whitestone Group acquires a 40% Stake in Thelema S.a r.l, a Special Purpose Vehicle (SPV) established for the ownership of B Medical Systems - News-Medical
Azenta announces completion of B Medical Systems sale to Thelema S.a r.l; Whitestone Group acquires a 40% Stake in Thelema S.a r.l, a Special Purpose Vehicle (SPV) established for the ownership of B Medical Systems News-Medical
Azenta (AZTA) After The B Medical Sale Is The New Focus Already Priced In - simplywall.st
Azenta (AZTA) After The B Medical Sale Is The New Focus Already Priced In simplywall.st
Azenta Completes Sale of B Medical Systems to Streamline Its Life Sciences Portfolio - Pulse 2.0
Azenta Completes Sale of B Medical Systems to Streamline Its Life Sciences Portfolio Pulse 2.0
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $0.1 | — | — | $149.28M | — | Scheduled |
| FY2026 Q2 | 2025. 03. 31. | Time TBD | — | $-1.29 | — | — | $290.77M | Reported |
| FY2026 Q1 | 2024. 12. 31. | Time TBD | — | $-0.25 | — | — | $147.44M | Reported |
| FY2025 Q3 | 2024. 06. 30. | Time TBD | — | $-2.9 | — | — | $422.37M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 07. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 04. 07. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 03. 17. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 02. 05. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 02. 05. | Jefferies | — | Maintain | Buy → Buy | — | Jefferies: Buy |
| 2026. 02. 05. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
As of FY2026Q2 · Source: SEC/DART + price data
No holdings data to show.